Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sun Pharma Advanced Research Company (SPARC) is a specialty pharmaceutical R&D company focused on developing novel drug delivery systems and new chemical entities, primarily for dermatology and ophthalmology indications. The company operates as a clinical-stage biotech with limited commercial revenue, burning significant cash to fund Phase II/III trials while seeking regulatory approvals and out-licensing opportunities in developed markets.
SPARC operates a capital-intensive R&D model, investing heavily in clinical trials for proprietary drug candidates with differentiated delivery mechanisms or novel formulations. Revenue is episodic and lumpy, driven by upfront licensing fees, milestone payments upon regulatory achievements, and eventual royalties on commercialized products. The company lacks pricing power until assets reach late-stage development or approval, relying on partnership economics rather than direct sales. Current negative margins reflect pre-commercialization stage with high clinical trial costs and regulatory expenses exceeding limited partnership revenue.
Clinical trial readouts for lead dermatology and ophthalmology candidates - positive Phase II/III data drives 20-40% single-day moves
FDA and EMA regulatory filing acceptances, priority review designations, or approval decisions for pipeline assets
Out-licensing deal announcements with upfront payments and milestone structures from Big Pharma partners
Cash runway updates and financing activities - equity raises or debt facilities signal development continuity or dilution concerns
Patent litigation outcomes or intellectual property challenges affecting proprietary delivery platforms
Clinical trial failure risk - Phase II/III assets have 30-50% probability of technical failure, which would eliminate associated revenue potential and require pipeline replenishment
Regulatory pathway uncertainty - FDA and EMA standards for novel delivery systems lack clear precedent, creating approval timeline and endpoint definition risks
Pricing pressure on specialty pharmaceuticals from government negotiations and payer pushback reduces royalty economics on future approvals
Large pharmaceutical companies developing in-house delivery platforms reduce demand for external licensing and compress deal valuations
Competing clinical-stage biotechs targeting same indications with alternative mechanisms create winner-take-all dynamics in partnership auctions
Generic and biosimilar competition eroding specialty pharma margins affects partner willingness to pay premium royalty rates
Extreme negative cash flow ($3.7B FCF deficit) and current ratio of 0.03 indicate acute liquidity stress requiring imminent financing or asset monetization
Negative debt-to-equity ratio and distorted ROE (125.2%) suggest negative shareholder equity, indicating accumulated losses exceed capital - potential balance sheet insolvency
Minimal cash runway forces binary outcomes - successful financing/partnership or wind-down scenario within 6-12 months based on burn rate
low - Clinical-stage pharmaceutical development operates independently of GDP cycles, as trial timelines and regulatory processes follow scientific and bureaucratic schedules rather than economic conditions. However, partnership deal flow and licensing valuations can compress during risk-off periods when Big Pharma curtails external innovation spending.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (royalties 5-10 years out), compressing biotech multiples. Financing costs increase if the company taps debt markets, though clinical-stage firms typically rely on equity. Higher rates also reduce Big Pharma appetite for speculative licensing deals as internal hurdle rates rise.
Moderate - While SPARC doesn't extend customer credit, its ability to secure non-dilutive financing (convertible debt, venture debt) depends on credit market conditions. Tight credit markets force reliance on dilutive equity raises. Partnership counterparty risk exists if licensees face financial distress and delay milestone payments.
growth - Speculative biotech investors seeking asymmetric returns from clinical trial success and regulatory approvals, willing to accept binary outcomes and high volatility. Current distressed financial profile attracts event-driven and special situations investors betting on restructuring or asset sales. Not suitable for value or income investors given negative profitability and no dividend.
high - Clinical-stage biotechs exhibit 60-100% annualized volatility driven by binary trial outcomes, regulatory decisions, and financing events. Single-day moves of 30-50% common around data readouts. Current financial distress adds restructuring risk premium to volatility.